# Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer

> **NCT00677144** · PHASE2 · COMPLETED · sponsor: **Hallym University Medical Center** · enrollment: 88 (actual)

## Conditions studied

- Colorectal Neoplasm

## Interventions

- **DRUG:** OS (oxalipaltin+S-1)
- **DRUG:** XELOX (oxalipaltin+capecitabine)

## Key facts

- **NCT ID:** NCT00677144
- **Lead sponsor:** Hallym University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2012-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677144, "Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00677144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*